Would it be possible for BOT management to seek exemption from a phase iii trial?
Epidiolex already has FDA approval with a CBD active...
and it wouldn't be the first time, Painkiller "Rexista RX" didn't need to go through phase iii because it was deemed "bioequivalent" to the already FDA approved OxyContin.
Thoughts?
Ann: Investor Presentation, page-47
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
33.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $707.4M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10000 | 34.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.0¢ | 50026 | 4 |
View Market Depth
| Last trade - 09.33am 26/11/2024 (20 minute delay) ? |
| BOT (ASX) Chart |
Day chart unavailable
